ALEC Stock Charts

Quarterly

Annual

Unit: USD	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31

cash flows from operating activities:
net income	-34,667,000	-30,524,000	-40,471,000	-2,074,000	-42,220,000	-38,676,000	-36,079,000	-41,434,000	-44,475,000	1,375,000	-45,857,000	-52,428,000	-46,148,000	9,883,000	-44,617,000	-55,608,000	126,597,000	-55,147,000	-52,171,000	-52,179,000	-52,704,000	-45,326,000	-40,019,000	-30,527,000	-31,738,000	-24,560,000	-18,560,000
adjustments to reconcile net income to net cash from operating activities:
depreciation and amortization	1,237,000	2,329,000	984,000	1,242,000	1,318,000	1,404,000	1,443,000	1,437,000	1,464,000	1,464,000	1,360,000	1,394,000	1,347,000	1,384,000	1,589,000	1,594,000	1,605,000	1,589,000	1,541,000	1,503,000	1,464,000	1,457,000	1,446,000	1,378,000	1,278,000	821,000	298,000
stock-based compensation	6,402,000	7,062,000	8,351,000	10,212,000	9,035,000	9,909,000	10,307,000	11,542,000	10,059,000	10,222,000	10,975,000	10,963,000	10,766,000	12,478,000	11,939,000	12,706,000	10,201,000	9,078,000	8,800,000	8,902,000	8,030,000	6,948,000	6,642,000	5,238,000	4,104,000	3,694,000	3,245,000
amortization of premiums and accretion of discounts on marketable securities	-1,548,000	-1,758,000	-2,027,000	-2,579,000	-3,263,000	-3,958,000	-4,579,000	-4,808,000	-4,591,000	-3,323,000	-2,596,000			148,000	570,000			558,000	594,000	576,000
amortization of right-of-use assets	1,095,000	893,000	864,000	836,000	873,000	877,000	848,000	821,000	793,000	767,000	742,000	719,000	696,000	673,000	670,000	552,000	496,000	477,000	461,000	461,000	326,000	311,000	297,000
amortization of debt discount and debt issuance costs	75,000	71,000	69,000
impairment of right-of-use assets and leasehold improvements	0
changes in operating assets and liabilities:
prepaid expenses and other current assets	2,621,000	201,000	-679,000	742,000	4,205,000	2,940,000	-2,361,000	-3,125,000	-3,702,000	1,855,000	-977,000	-831,000	-816,000	186,000	-2,465,000	1,514,000	1,175,000	2,233,000	-3,790,000	95,000	-1,850,000	1,221,000	-3,305,000	-327,000	-373,000	1,855,000	-2,751,000
other assets	23,000	24,000	26,000	1,544,000	27,000	1,287,000	16,000	1,130,000	57,000	199,000	-2,395,000	-625,000	135,000	13,000	-358,000	142,000	277,000	-3,401,000	25,000	-400,000	-1,131,000	-683,000	-284,000	30,000	-89,000	0	17,000
accounts payable	2,540,000	-109,000	111,000	-2,774,000	690,000	-275,000	918,000	-1,015,000	4,000	1,548,000	-914,000	-189,000	147,000	-2,573,000	2,043,000	2,264,000	-9,495,000	6,556,000	2,592,000	1,322,000	-3,344,000	1,296,000	3,135,000	20,000	-282,000	-269,000	683,000
accrued liabilities and accrued clinical supply costs	2,514,000	-3,785,000	-12,722,000	6,805,000	3,366,000	473,000	-10,304,000	-2,121,000	8,049,000	3,638,000	-7,020,000	4,632,000	-1,112,000	-2,792,000	-3,383,000	7,879,000	-1,263,000	1,275,000	-5,500,000	-2,795,000	14,508,000	-7,286,000	7,805,000	1,743,000	1,624,000	6,795,000	-952,000
payable to collaboration partner	4,181,000	-2,438,000	3,131,000	-858,000	959,000	-9,819,000	7,929,000
deferred revenue	-3,260,000	-7,874,000	-3,674,000	-54,240,000	-15,342,000	-15,083,000	-15,893,000	-15,190,000	-2,284,000	-50,559,000	1,251,000	-14,440,000	-14,852,000	-79,851,000	175,526,000	-13,994,000	317,587,000	-6,568,000	-4,110,000	-4,853,000	-5,904,000	-3,170,000	-7,171,000	-6,001,000	-2,696,000	-6,917,000	-5,605,000
refund liability to collaboration partner	-12,041,000	-12,724,000	-13,339,000	-12,371,000	-11,113,000	-10,293,000	-12,230,000	-10,680,000	-8,007,000
lease liabilities	-1,683,000	-1,615,000	-1,567,000	-1,513,000	-1,474,000	-1,444,000	-1,361,000	-1,318,000	-1,267,000	-1,239,000	-1,144,000	-1,118,000	-1,092,000	-1,069,000	-995,000	-1,020,000	-978,000	-1,193,000	-821,000	-364,000	-715,000	-700,000	-628,000
other long-term liabilities	0	50,000	160,000	0	0			475,000	0	0	139,000	526,000	0			0	0	0	-314,000
net cash from operating activities	-32,511,000	-49,046,000	-60,783,000	-55,028,000	-50,734,000	-62,797,000	-61,346,000	-46,070,000	-46,540,000	-43,004,000	-48,548,000	-48,925,000	-49,053,000	-57,442,000	135,091,000	-49,265,000	445,052,000	-44,543,000	-52,693,000	-47,658,000	-40,821,000	-45,942,000	-32,313,000	-28,827,000	-28,863,000	-18,052,000	-23,566,000
capex	-11,000	-10,000	-20,000	-173,000	-212,000	-337,000	-533,000	-233,000	94,000	-1,217,000	-1,025,000	-766,000	-1,915,000	-744,000	-692,000	-557,000	-915,000	-828,000	-947,000	-788,000	-381,000	-297,000	-3,566,000	-1,573,000	-2,299,000	-9,363,000	-2,030,000
free cash flows	-32,522,000	-49,056,000	-60,803,000	-55,201,000	-50,946,000	-63,134,000	-61,879,000	-46,303,000	-46,446,000	-44,221,000	-49,573,000	-49,691,000	-50,968,000	-58,186,000	134,399,000	-49,822,000	444,137,000	-45,371,000	-53,640,000	-48,446,000	-41,202,000	-46,239,000	-35,879,000	-30,400,000	-31,162,000	-27,415,000	-25,596,000
cash flows from investing activities:
purchase of property and equipment	-11,000	-10,000	-20,000	-173,000	-212,000	-337,000	-533,000	-233,000	94,000	-1,217,000	-1,025,000	-766,000	-1,915,000	-744,000	-692,000	-557,000	-915,000	-828,000	-947,000	-788,000	-381,000	-297,000	-3,566,000	-1,573,000	-2,299,000	-9,363,000	-2,030,000
purchase of marketable securities	-58,952,000	-76,085,000	-55,794,000	-86,621,000	-83,351,000	-101,303,000	-196,466,000	-137,251,000	-145,972,000	-148,232,000	-120,274,000	-162,553,000	-73,055,000	-291,176,000	-30,114,000	-203,686,000	-134,635,000			-91,860,000	-107,561,000	-104,482,000	-202,906,000	-118,370,000	-71,792,000	-72,215,000	-267,232,000
maturities of marketable securities	108,505,000	128,836,000	121,549,000	127,485,000	123,911,000	136,929,000	185,234,000	152,050,000	162,839,000	127,634,000	210,000,000	181,700,000	135,500,000	66,101,000	18,700,000	57,490,000	55,800,000	62,500,000	110,500,000	104,200,000	140,955,000	80,035,000	81,600,000	150,000,000	120,000,000	108,000,000	118,000,000
sale of marketable securities	0			711,000	0											0
net cash from investing activities	49,542,000	55,722,000	65,735,000	41,402,000	40,348,000	37,146,000	-11,765,000	18,071,000	16,961,000	-21,815,000	88,701,000	18,381,000	60,530,000	-225,819,000	-12,106,000	-146,753,000	-69,054,000	56,591,000	109,553,000	11,552,000	33,013,000	-24,744,000	-124,872,000	30,057,000	45,909,000	26,422,000	-151,262,000
cash flows from financing activities:
proceeds from issuance of common stock, net of issuance costs
purchase of common stock under employee stock purchase plan	0				0																0
net cash from financing activities	14,701,000			9,788,000	0	644,000	71,108,000	590,000	0	881,000	1,079,000	636,000	489,000	906,000	2,483,000	8,638,000	14,821,000	2,962,000	3,874,000	1,096,000	286,000	2,270,000	228,461,000	1,437,000	720,000	-116,000	170,312,000
net increase in cash, cash equivalents, and restricted cash	31,732,000	6,798,000	4,952,000				-2,003,000			-63,938,000	41,232,000	-29,908,000	11,966,000	-282,355,000	125,468,000	-187,380,000	390,819,000	15,010,000	60,734,000	-35,010,000	-7,522,000	-68,416,000	71,276,000	2,667,000	17,766,000	8,254,000	-4,516,000
cash, cash equivalents, and restricted cash at beginning of period	0	0	34,867,000	0	0	0	76,101,000	0	0	0	155,795,000	0	0	0	330,624,000	0	0	0	51,441,000	0	0	0	91,113,000	0	0	0	66,942,000
cash, cash equivalents, and restricted cash at end of period	31,732,000	6,798,000	39,819,000	-3,838,000	-10,386,000	-25,007,000	74,098,000	-27,409,000	-29,579,000	-63,938,000	197,027,000	-29,908,000	11,966,000	-282,355,000	456,092,000	-187,380,000	390,819,000	15,010,000	112,175,000	-35,010,000	-7,522,000	-68,416,000	162,389,000	2,667,000	17,766,000	8,254,000	62,426,000
non-cash investing and financing activities:
property and equipment purchases included in accounts payable and accrued liabilities					-158,000	154,000	31,000	-29,000	-552,000	448,000	305,000	-140,000	-312,000	446,000	499,000	469,000	-112,000	-280,000	628,000	91,000	153,000	6,000	178,000				1,071,000
interest paid	2,000	2,000	214,000
proceeds from issuance of common stock upon public offering, net of issuance costs				0	0	0	71,108,000
impairment loss of right-of-use assets and leasehold improvements
income from disposal of fixed assets
receivable from collaboration partner								10,465,000	-2,640,000	-3,126,000	-2,112,000	3,904,000	2,325,000	4,003,000	-5,428,000	-5,807,000
proceeds from the exercise of options to purchase common stock								0	0	0	1,079,000	46,000	489,000	41,000	2,483,000	7,842,000	14,821,000	1,993,000	3,874,000	632,000	286,000	2,196,000	3,217,000	731,000	720,000	63,000	5,000
proceeds from issuance of stock from employee stock purchase plan
proceeds from debt financing, net of discount and issuance costs
net decrease in cash, cash equivalents, and restricted cash				-3,838,000	-10,386,000
impairment loss of right-of-use asset and leasehold improvements
purchase of common stock under employee stock option plan																	0
impairment loss on right-of-use assets
income from disposal of property and equipment																				95,000	3,000	0	9,000	0	0
proceeds from issuance of common stock upon public offerings, net of issuance costs
accretion of discounts on marketable securities
deferred offering costs in accrued liabilities
tenant improvements paid by landlord																								0	0	0	8,286,000
impairment loss on right-of-use-assets
proceeds from issuance of common stock upon follow-on public offering, net of issuance costs																					0	-641,000	225,244,000
deferred offering costs in accounts payable and accrued liabilities																							641,000
proceeds from issuance of common stock upon initial public offering, net of issuance costs																								0	0	-179,000	170,307,000
proceeds from issuance of common stock upon follow-on public offering, net of issuance cost
proceeds from issuance of convertible preferred stock, net of issuance costs
impairment loss on right-of-use asset																								0	0
deferred rent																								0	0	0	-44,000
accretion of discount on marketable securities																						-10,000	-240,000	-674,000	-1,170,000	-1,536,000	-1,321,000
payment of deferred offering costs
issuance costs for convertible preferred stock included in accounts payable
accounts receivable
lease liabilities and other long-term liabilities																									479,000	868,000	1,424,000
property and equipment purchases included in accrued liabilities																									826,000
deferred offering costs for initial public offering included in accounts payable and accrued liabilities																											179,000
issuance costs for convertible preferred stock included in accrued liabilities
payment of convertible preferred stock issuance costs
payment of deferred offering costs for initial public offering
deferred offering costs for initial public offering included in accrued liabilities

The information provided in this report is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.